MCID: ACT135
MIFTS: 53

Acute Graft Versus Host Disease malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Acute Graft Versus Host Disease

About this section
Sources:
31ICD10 via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 48 54
Acute Graft-Versus-Host Disease 50
 
Acute Gvh Disease 68
Acute Gvhd 48

Classifications:



External Ids:

Orphanet54 ORPHA99920
ICD10 via Orphanet31 T86.0

Summaries for Acute Graft Versus Host Disease

About this section
MalaCards based summary: Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to hepatitis and clostridium difficile colitis. An important gene associated with Acute Graft Versus Host Disease is TNF (Tumor Necrosis Factor), and among its related pathways are Cellular roles of Anthrax toxin and Hypertrophy Model. Affiliated tissues include t cells, bone and bone marrow, and related mouse phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and neoplasm.

Related Diseases for Acute Graft Versus Host Disease

About this section

Diseases in the Acute Graft Versus Host Disease family:

Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 246)
idRelated DiseaseScoreTop Affiliating Genes
1hepatitis30.0IFNG, IL10, IL2, TNF
2clostridium difficile colitis29.7IFNG, IL2, IL4, TNF
3hematopoietic stem cell transplantation10.7
4leukemia10.4
5pyridoxal 5'-phosphate-dependent epilepsy10.3IL10, TNF
6steatitis10.3IL2, TNF
7myoglobinuria recurrent10.3IFNG, IL4
8stocco dos santos syndrome10.3IFNG, TNF
9paralytic poliomyelitis10.3IFNG, IL2
10caplan's syndrome10.3IFNG, IL2
11sarcoma10.2IL2, IL4
12vulvar vestibulitis syndrome10.2IL2, IL4
13multiple vertebral anomalies unusual facies10.2IL10, TNF
14ceroid lipofuscinosis, neuronal, 310.2IL10, IL4
15chronic thromboembolic pulmonary hypertension10.2IFNG, IL10, IL2
16tau syndrome10.2IL18, TNF
17senile reticular retinal degeneration10.2IFNG, IL10, TNF
18conduct disorder10.2IFNG, IL10, TNF
19pancreatic signet ring cell adenocarcinoma10.2IFNG, IL10, TNF
20oropharynx cancer10.2IFNG, IL10, IL2
21pulpitis10.2IFNG, IL10, TNF
22ciliary discoordination, due to random ciliary orientation10.2IFNG, IL10, IL2RA
23hereditary alpha tryptasemia syndrome10.2IFNG, IL10, TNF
24rickettsialpox10.2IFNG, IL10, TNF
25diabetic angiopathy10.2IL10, IL4
26plummer's disease10.2IFNG, IL10, TNF
27endotheliitis10.2
28hemangioma of intra-abdominal structure10.2FASLG, IFNG
29disease of mental health10.2IFNG, IL10, TNF
30follicular adenoma10.2IFNG, IL10, TNF
31tungiasis10.2IFNG, IL10, IL4
32centronuclear myopathy 510.2IFNG, IL10, IL4
33tubular renal disease-cardiomyopathy syndrome10.2IL10, IL4, TNF
34depressed scar10.2IFNG, IL10, TNF
35strawberry gallbladder10.2IFNG, IL2, TNF
36lagophthalmos10.2IL10, IL4, TNF
37distal trisomy 14q10.2IFNG, TNF
38conidiobolomycosis10.2IL10, IL4, TNF
39classic type lipoma10.2IFNG, IL10, TNF
40multiple epiphyseal dysplasia due to collagen 9 anomaly10.2IFNG, IL2, IL4
41vestibule of mouth cancer10.2IL10, IL4, TNF
42t-cell prolymphocytic leukemia10.2IL2RA, TNF
43loiasis10.2IFNG, IL10, IL4
44congenital hypothyroidism10.2IL10, IL4, TNF
45fungal gastritis10.2IFNG, IL10, TNF
46proximal symphalangism10.2IFNG, IL10, IL4
47lung combined large cell neuroendocrine carcinoma10.2IL10, IL2, IL4
48urethral intrinsic sphincter deficiency10.2IFNG, IL4, TNF
49sclerosing adenosis of breast10.2IFNG, IL10, TNF
50hypotrichosis 410.2IFNG, IL4, TNF

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to acute graft versus host disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

About this section

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-15.4FASLG, GZMB, IL10, IL18, IL2, IL2RA

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.4FASLG, IFNG, IL10, IL2, TNF
2MP:00030128.8IFNG, IL10, IL2, IL4, MYH9, TNF
3MP:00053798.8FASLG, IFNG, IL10, IL2, IL2RA, IL4
4MP:00053708.5FASLG, IFNG, IL10, IL2, IL4, TNF
5MP:00107718.5FASLG, IFNG, IL10, IL18, IL4, TNF
6MP:00053888.2FASLG, IFNG, IL10, IL2, IL2RA, IL4
7MP:00053817.4FASLG, IFNG, IL10, IL18, IL2, IL2RA
8MP:00053787.2IFNG, IL10, IL18, IL2, IL2RA, IL4
9MP:00053846.9FASLG, IFNG, IL10, IL18, IL2, IL4
10MP:00053916.7FASLG, IFNG, IL10, IL18, IL2, IL2RA
11MP:00053976.6FASLG, IFNG, IL10, IL18, IL2, IL2RA
12MP:00053766.6FASLG, IFNG, IL10, IL18, IL2, IL2RA
13MP:00053876.6FASLG, IFNG, IL10, IL18, IL2, IL2RA
14MP:00107686.6FASLG, IFNG, IL10, IL18, IL2, IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

About this section

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 386)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
2
Cyclophosphamideapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
3
ThiotepaapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122652-24-45453
Synonyms:
 
Thioplex
4
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
6
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
Tacrolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
8
Basiliximabapproved, investigationalPhase 4, Phase 3, Phase 2138152923-56-3, 179045-86-4
Synonyms:
 
Ig gamma-1 chain C region
chimeric mouse-human antiCD25
9
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
10
Cytarabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11117147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine (JP15/USP/INN)
Cytarabine [USAN:INN:BAN:JAN]
 
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
11
VidarabineapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 152124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
12
FludarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
13
Busulfanapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
14
Mycophenolic acidapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 195224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
15
Ganciclovirapproved, investigationalPhase 4, Phase 3, Phase 215382410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
16
MethotrexateapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 115511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
17
FoscarnetapprovedPhase 4, Phase 23363585-09-1, 4428-95-93415
Synonyms:
1nki
34156-56-4
4428-95-9
4428-95-9 (Parent)
63585-09-1
63585-09-1 (tri-hydrochloride salt)
79510_FLUKA
A 29622
A-29622
AC-2085
AC1L1FVT
AC1L2C37
AC1L5400
AC1NB82R
AC1Q1UNV
AR-1L5079
Ambap63585-09-1
BSPBio_003067
C06456
CHEBI:127780
CHEBI:141644
CHEBI:60269
CHEMBL666
CHEMBL754
CID169569
CID3415
CID44561
Carboxyphosphonic acid
D00579
D02267
DB00529
DRG-0017
Dihydroxyphosphinecarboxylic acid oxide
Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody
Dihydroxyphosphinecarboxylic acid oxide trisodium salt
Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate
DivK1c_000915
EHB 776
EHB-776
FOSCARNET SODIUM
Formic acid, phosphono-, trisodium salt, hexahydrate
Forscarnet sodium
Foscarmet
Foscarnet & IFN-.ALPHA.
Foscarnet sodico
Foscarnet sodico [Spanish]
Foscarnet sodique
Foscarnet sodique [French]
Foscarnet sodique [INN-French]
Foscarnet sodium (USAN/INN)
Foscarnet sodium [USAN:INN:BAN]
Foscarnet sodium hydrate
Foscarnet sodium hydrate (JAN)
Foscarneto sodico
Foscarneto sodico [INN-Spanish]
Foscarnetum natricum
Foscarnetum natricum [INN-Latin]
Foscarnetum natricum [Latin]
Foscavir
Foscavir (TN)
HMS1921D18
HMS2092N15
HMS502N17
 
HS-0008
IDI1_000915
KBio1_000915
KBio2_001839
KBio2_004407
KBio2_006975
KBio3_002567
KBioGR_001419
KBioSS_001839
LS-105952
LS-105953
LS-183979
LS-187063
LS-187793
MSL & PFA
MolPort-003-665-560
MolPort-003-895-968
NCGC00094941-01
NCGC00094941-02
NChemBio.2007.9-comp7
NINDS_000915
NSC313410
P6801_ALDRICH
P6801_SIGMA
PFA & rIFN.alpha.A
Phgosphonocarboxylic acid
Phosphinecarboxylic acid, dihydroxy-, oxide
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
Phosphonoformate
Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon
Phosphonoformic acid
Phosphonoformic acid & IFN-.ALPHA.
Phosphonoformic acid trisodium salt hexahydrate
Phosphonoformic acid, trisodium salt
Phosphonoformic acid, trisodium salt, hexahydrate
Phosphonomethanoic acid
Prestwick_1024
SPBio_000735
SPECTRUM1502019
Sodium phosphonoformate tribasic hexahydrate
Spectrum2_000668
Spectrum3_001484
Spectrum4_000840
Spectrum5_000932
Spectrum_001359
Triapten
Trisodium carboxyphosphate
Trisodium phosphonoformate
Trisodium phosphonoformate hexahydrate
Trisodium phosphonoformte hexahydrate
UNII-364P9RVW4X
UNII-964YS0OOG1
Virudin
dihydroxyphosphanecarboxylic acid oxide
foscarnet
foscarnet sodium hexahydrate
phosphonomethanoic acid
sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6)
trisodium carboxyphosphate (anhydrous)
trisodium dioxidophosphanecarboxylate oxide
trisodium dioxidophosphinecarboxylate oxide
trisodium phosphonatoformate
trisodium phosphonatoformate hexahydrate
trisodium phosphonoformate (anhydrous)
18
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
19
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
20
MentholapprovedPhase 4, Phase 2, Phase 126062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
21
InfliximabapprovedPhase 4, Phase 2, Phase 1392170277-31-3
Synonyms:
 
Ig gamma-1 chain C region
Remicade
22
Daclizumabapproved, investigationalPhase 4, Phase 3, Phase 298152923-56-3
Synonyms:
 
Dacliximab
Daclizumab beta
23
Posaconazoleapproved, investigational, vet_approvedPhase 456171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
24
Peginterferon alfa-2bapprovedPhase 430799210-65-8, 215647-85-1
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
 
Peginterferon alfa-2b
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron (TN)
Unitron PEG
25
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
26
leucovorinapproved, NutraceuticalPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
27
Phosphonoacetic AcidexperimentalPhase 4, Phase 2334408-78-0546
Synonyms:
Carboxymethanephosphonate
Carboxymethanephosphonic acid
Disodium carboxymethylphosphonate
Disodium phosphonoacetate
Disodium phosphonoacetate monohydrate
Fosfonet
Fosfonet sodium
 
Fosfonoacetate
Fosfonoacetic acid
Lopac-P-6909
PAE
PPA
Phosphonacetate
Phosphonacetic acid
Phosphonoacetate
Phosphonoacetic acid
28Anti-Retroviral AgentsPhase 4, Phase 2, Phase 13296
29Ganciclovir triphosphatePhase 4, Phase 3, Phase 2153
30ImmunoglobulinsPhase 4, Phase 2, Phase 3, Phase 16394
31Antibodies, MonoclonalPhase 4, Phase 2, Phase 3, Phase 14039
32Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113086
33Reverse Transcriptase InhibitorsPhase 4, Phase 21913
34Antirheumatic AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 110956
35Nucleic Acid Synthesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 14962
36AntibodiesPhase 4, Phase 2, Phase 3, Phase 16394
37Folic Acid AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 12257
38
TreosulfanPhase 4, Phase 3, Phase 232299-75-29296
Synonyms:
(2S,3S)-Threitol 1,4-bismethanesulfonate
1,4-Dimethanesulfonate(2S,3S)-Threitol
1,4-DimethanesulfonateL-(+ )-Threitol
1,4-DimethanesulfonateL-Threitol
DHB
Dihydroxybusulfan
 
Dihydroxymyleran
L-Threitol 1,4-dimethanesulfonate
L-Threitol, 1, 4-bis(methanesulfonate)
L-Threitol-1, 4-bis(methanesulfonate)
L-Threitol-1,4-bis(methanesulfonate)
L-Threityl dimesylate
Tresulfan
39Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
40Dermatologic AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15806
41Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13696
42Antiviral AgentsPhase 4, Phase 2, Phase 3, Phase 19967
43Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17361
44Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15592
45Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
46Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
47glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 15103
48Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 122062
49HormonesPhase 4, Phase 3, Phase 2, Phase 114415
50Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17180

Interventional clinical trials:

(show top 50)    (show all 996)
idNameStatusNCT IDPhase
1Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHDCompletedNCT00574470Phase 4
2Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation FroCompletedNCT02660684Phase 4
3Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCTCompletedNCT01232504Phase 4
4A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant RecipientsCompletedNCT00195429Phase 4
5Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking SirolimusCompletedNCT00195468Phase 4
6Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
7Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia MajorRecruitingNCT02342145Phase 4
8Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTRecruitingNCT02677181Phase 4
9Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCTRecruitingNCT02634294Phase 4
10Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral DonorsRecruitingNCT02412423Phase 4
11Anti-thymocyte Globulins for Graft-versus-host Disease ProphylaxisRecruitingNCT01856803Phase 4
12Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal InfectionsRecruitingNCT02805946Phase 4
13Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML PatientsRecruitingNCT03150134Phase 4
14CMV-CTL for the Treatment of CMV Infection After HSCTRecruitingNCT03004261Phase 4
15ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)RecruitingNCT02670564Phase 4
16Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorRecruitingNCT03171831Phase 4
17Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationNot yet recruitingNCT02784561Phase 4
18A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTNot yet recruitingNCT03176849Phase 4
19Extracorporeal Photopheresis for Acute Graft Versus Host DiseaseUnknown statusNCT00179855Phase 2, Phase 3
20MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) ProphylaxisUnknown statusNCT02270307Phase 2, Phase 3
21Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell TransplantationUnknown statusNCT00934557Phase 3
22Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow TransplantationUnknown statusNCT00207792Phase 3
23Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaUnknown statusNCT01423747Phase 3
24ALL-SCT BFM International- HSCT in Children and Adolescents With ALLUnknown statusNCT01423500Phase 3
25Thymoglobulin in Unrelated Hematopoietic Progenitor Cell TransplantationUnknown statusNCT01217723Phase 3
26Hematopoietic Stem Cell Transplantation for MucopolysaccharidosisUnknown statusNCT01238328Phase 2, Phase 3
27Hematopoietic Stem Cell Transplantation for Malignant Infantile OsteopetrosisUnknown statusNCT01087398Phase 2, Phase 3
28Unrelated Double Umbilical Cord Blood Units TransplantationUnknown statusNCT01015742Phase 2, Phase 3
29Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid LeukaemiaUnknown statusNCT00224614Phase 3
30The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host DiseaseCompletedNCT00726375Phase 3
31Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host DiseaseCompletedNCT00035880Phase 2, Phase 3
32Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host DiseaseCompletedNCT00929695Phase 3
33Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host DiseaseCompletedNCT00366145Phase 3
34Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host DiseaseCompletedNCT00053976Phase 3
35Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHDCompletedNCT00562497Phase 3
36Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)CompletedNCT00655343Phase 3
37Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)CompletedNCT01002742Phase 3
38Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host DiseaseCompletedNCT01788501Phase 2, Phase 3
39Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
40Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow TransplantationCompletedNCT00002456Phase 3
41Thymoglobuline in Non-myeloablative Allogeneic Stem-cell TransplantationCompletedNCT00130754Phase 3
42Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3
43Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute LeukemiaCompletedNCT00678275Phase 3
44Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell TransplantationCompletedNCT00180089Phase 3
45Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell TransplantationCompletedNCT00993343Phase 3
46Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow TransplantationCompletedNCT00004255Phase 2, Phase 3
47Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell TransplantationCompletedNCT01020175Phase 3
48Stem Cell Transplant for Inborn Errors of MetabolismCompletedNCT00176904Phase 2, Phase 3
49Nonmyeloablative Stem Cell Transplant in ElderlyCompletedNCT00382759Phase 2, Phase 3
50C-Reactive Protein as a Predictor of Stem Cell Transplant ComplicationsCompletedNCT00179868Phase 2, Phase 3

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

About this section

Anatomical Context for Acute Graft Versus Host Disease

About this section

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

36
T cells, Bone, Bone marrow, Liver, Skin, Endothelial, Myeloid

Publications for Acute Graft Versus Host Disease

About this section

Articles related to Acute Graft Versus Host Disease:

(show top 50)    (show all 710)
idTitleAuthorsYear
1
The Combination of Cyclosporine and Mycophenolate Mofetil is Less Effective than Cyclosporine and Methotrexate in the Prevention of Acute Graft-versus Host Disease after Stem-cell Transplantation from Unrelated Donors. (28052467)
2017
2
Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (27766393)
2017
3
Cutaneous acute graft-versus-host disease with isomorphic disposition over striae distensae in a 12-year-old girl. (27805255)
2017
4
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. (28088653)
2017
5
The role of danger signals and ectonucleotidases in acute graft-versus-host disease. (26902992)
2016
6
Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. (27461930)
2016
7
Treatment of acute graft-versus-host disease. (27795528)
2016
8
Circulating miRNA panel for prediction of acute graft-versus-host disease inA lymphoma patients undergoing matched unrelated hematopoietic stem cellA transplantation. (27013207)
2016
9
The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease. (27818661)
2016
10
Pretransplant I^2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. (27044906)
2016
11
Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. (27375156)
2016
12
GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation. (27391226)
2016
13
Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. (27649744)
2016
14
Organsiderosis and hemophagocytosis during acute graft-versus-host disease. (27198715)
2016
15
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. (27498124)
2016
16
IL-22 promoted CD3+ T cell infiltration by IL-22R induced STAT3 phosphorylation in murine acute graft versus host disease target organs after allogeneic bone marrow transplantation. (27551984)
2016
17
The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. (26714122)
2016
18
Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation. (27408705)
2016
19
Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. (27091717)
2016
20
Donor Killer Immunoglobulin-Like Receptor Haplotype B/X Induces Severe Acute Graft-Versus-Host Disease in the Presence of HLA Mismatch in T-Cell Replete Hematopoietic Cell Transplantation. (28042021)
2016
21
Donor-Derived Regulatory T Cells Attenuate the Severity of Acute Graft-Versus-Host Disease after Cord Blood Transplantation. (27356468)
2016
22
Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease. (27137185)
2016
23
Successful salvage treatment of acute graft-versus-host disease after liver transplantation by withdrawal of immunosuppression: a case report. (26925149)
2016
24
Correlation of Tc17 cells at early stages after allogeneic hematopoietic stem cell transplantation with acute graft-versus-host disease. (27846420)
2016
25
A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. (27664325)
2016
26
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. (27389386)
2016
27
Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are Associated With Decreased Serum Levels of Adiponectin and an Increased Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase. (27931514)
2016
28
Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. (27625357)
2016
29
Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. (27902756)
2016
30
Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. (27751764)
2016
31
Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease. (27990387)
2016
32
High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. (26768690)
2016
33
miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. (27014257)
2016
34
High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg. (27168057)
2016
35
Effect of Everolimus (RAD001) on Acute Graft-Versus-Host Disease in Mice. (27379528)
2016
36
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. (27965986)
2016
37
T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. (26903480)
2016
38
Recombinant IL-7/HGFI^ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking. (27447780)
2016
39
Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. (27595281)
2016
40
Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. (27619472)
2016
41
Endothelial microparticles carrying hedgehog-interacting protein induce continuous endothelial damage in the pathogenesis of acute graft-versus-host disease. (27009877)
2016
42
Vascular alterations in a murine model of acute graft-versus-host disease are associated with decreased serum levels of adiponectin and an increased activity and vascular expression of indoleamine 2,3-dioxygenase. (27196361)
2016
43
A mathematical model provides new insights into solid organ transplant-associated acute graft-versus-host disease. (27465565)
2016
44
Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. (27528221)
2016
45
The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. (27829829)
2016
46
miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase. (27340781)
2016
47
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease. (26968790)
2016
48
Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. (26988741)
2016
49
Treatment of acute graft versus host disease with mesancyhmal stem cells: Questions and answers. (26969103)
2016
50
Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation. (26602146)
2016

Variations for Acute Graft Versus Host Disease

About this section

Expression for genes affiliated with Acute Graft Versus Host Disease

About this section
Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for genes affiliated with Acute Graft Versus Host Disease

About this section

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50)    (show all 62)
idSuper pathwaysScoreTop Affiliating Genes
19.8IL18, TNF
29.8IFNG, IL18
39.8NOD2, TNF
4
Show member pathways
9.6IFNG, IL2, TNF
59.6IFNG, IL2, TNF
6
Show member pathways
9.6IFNG, IL2, IL2RA
79.6IFNG, IL10, TNF
89.5IFNG, IL18, TNF
99.5IFNG, IL18, TNF
109.5IL2RA, IL4, TNF
119.4IFNG, IL2, IL4
129.3FASLG, IFNG, TNF
13
Show member pathways
9.2GZMB, IFNG, IL4
149.2IFNG, IL10, IL2, TNF
159.2IFNG, IL10, IL2, IL2RA
169.2IFNG, IL18, IL2, IL2RA
179.2IFNG, IL10, IL18, TNF
189.2IFNG, IL2, IL4, TNF
19
Show member pathways
9.2IFNG, IL2, IL4, TNF
209.2IFNG, IL2, IL2RA, IL4
21
Show member pathways
9.2IFNG, IL10, IL4, TNF
229.1IFNG, IL18, IL4, TNF
239.1IL10, IL18, IL4, TNF
24
Show member pathways
9.1FASLG, TNF, TNFRSF4
25
Show member pathways
9.0IFNG, IL18, MYH9
269.0FASLG, IFNG, IL2, TNF
27
Show member pathways
8.9FASLG, IFNG, IL4, TNF
28
Show member pathways
8.9IFNG, IL10, IL18, IL2, TNF
29
Show member pathways
8.9IFNG, IL10, IL18, IL2, TNF
308.8FASLG, IL2, IL2RA, IL4
31
Show member pathways
8.8FASLG, IL2, IL2RA, IL4
328.8IFNG, IL10, IL2, IL4, TNF
33
Show member pathways
8.8IFNG, IL10, IL2, IL4, TNF
34
Show member pathways
8.8IFNG, IL10, IL2, IL2RA, IL4
358.7IFNG, IL10, IL18, NOD2, TNF
368.6IL10, IL2RA, IL4, TNF, TNFRSF4
37
Show member pathways
8.6FASLG, IFNG, IL10, IL2, TNF
388.6IFNG, IL10, IL2, IL4, TNFRSF4
398.6FASLG, IFNG, IL10, IL18, TNF
408.5IFNG, IL10, IL2, IL2RA, IL4, TNF
41
Show member pathways
8.5IFNG, IL10, IL18, IL2, IL4, TNF
428.5FASLG, IL10, IL18, IL4, TNF
438.3IFNG, IL10, IL2, IL2RA, IL4, TNFRSF4
44
Show member pathways
8.3FASLG, IFNG, IL2, IL2RA, IL4, TNF
45
Show member pathways
8.2IFNG, IL10, IL18, IL2, IL2RA, IL4
46
Show member pathways
8.2IFNG, IL10, IL18, IL2, IL2RA, IL4
478.1FASLG, IL10, IL18, IL2, IL4, TNF
48
Show member pathways
8.0FASLG, GZMB, IFNG, IL2, IL4, TNF
49
Show member pathways
7.9FASLG, IFNG, IL18, IL2, IL2RA, IL4
50
Show member pathways
7.8FASLG, GZMB, IFNG, IL10, IL2, IL2RA

GO Terms for genes affiliated with Acute Graft Versus Host Disease

About this section

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098979.4FASLG, IFNG, IL2RA, IL4, TNF
2cell surfaceGO:00099869.1FASLG, IL2RA, NOD2, TNF, TNFRSF4
3extracellular regionGO:00055768.6FASLG, IFNG, IL10, IL18, IL2, IL4
4extracellular spaceGO:00056157.8FASLG, IFNG, IL10, IL18, IL2, IL4

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of calcidiol 1-monooxygenase activityGO:006055910.7IFNG, TNF
2endothelial cell apoptotic processGO:007257710.6IL10, TNF
3positive regulation of membrane protein ectodomain proteolysisGO:005104410.6IFNG, TNF
4positive regulation of osteoclast differentiationGO:004567210.6IFNG, TNF
5positive regulation of protein complex assemblyGO:003133410.6IFNG, TNF
6negative regulation of lymphocyte proliferationGO:005067210.6IL2, IL2RA
7negative regulation of cytokine secretion involved in immune responseGO:000274010.6IL10, TNF
8positive regulation of heterotypic cell-cell adhesionGO:003411610.6IL10, TNF
9negative regulation of myoblast differentiationGO:004566210.6IL18, TNF
10positive regulation of NF-kappaB import into nucleusGO:004234610.6IL18, TNF
11natural killer cell activationGO:003010110.5IL18, IL2
12positive regulation of mononuclear cell migrationGO:007167710.5IL4, TNF
13negative regulation of T-helper 17 cell differentiationGO:200032010.5IL2, IL4
14positive regulation of tissue remodelingGO:003410510.5IL18, IL2
15positive regulation of NIK/NF-kappaB signalingGO:190122410.5NOD2, TNF
16negative regulation of nitric oxide biosynthetic processGO:004501910.5IL10, IL4
17positive regulation of vitamin D biosynthetic processGO:006055710.5IFNG, TNF
18positive regulation of interleukin-1 beta secretionGO:005071810.5IFNG, NOD2
19regulation of T cell homeostatic proliferationGO:004601310.4IL2, IL2RA
20positive regulation of vascular smooth muscle cell proliferationGO:190470710.4IL10, TNF
21receptor biosynthetic processGO:003280010.4IL10, TNF
22positive regulation of immunoglobulin secretionGO:005102410.4IL2, TNFRSF4
23positive regulation of interleukin-10 productionGO:003273310.3IL4, NOD2
24cellular response to lipopolysaccharideGO:007122210.3IFNG, IL10, TNF
25necroptotic signaling pathwayGO:009752710.3FASLG, TNF
26inflammatory cell apoptotic processGO:000692510.3FASLG, IFNG
27negative regulation of growth of symbiont in hostGO:004413010.3IFNG, IL10, TNF
28positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.3IL2, IL4
29negative regulation of inflammatory responseGO:005072810.3IL10, IL2, IL2RA
30regulation of isotype switchingGO:004519110.3IL10, IL4
31positive regulation of interferon-gamma productionGO:003272910.2IL18, IL2, TNF
32positive regulation of chemokine biosynthetic processGO:004508010.2IFNG, IL4, TNF
33defense response to protozoanGO:004283210.2IFNG, IL10, IL4
34positive regulation of T cell differentiationGO:004558210.2IL2, IL2RA, IL4
35positive regulation of isotype switching to IgG isotypesGO:004830410.2IFNG, IL2, IL4
36positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.2IL10, IL4, TNF
37cellular response to organic cyclic compoundGO:007140710.2IL18, NOD2, TNF
38positive regulation of MHC class II biosynthetic processGO:004534810.2IFNG, IL10, IL4
39extrinsic apoptotic signaling pathwayGO:009719110.1FASLG, IFNG, TNF
40positive regulation of interleukin-17 productionGO:003274010.1IL18, IL2, NOD2
41MAPK cascadeGO:000016510.0IL18, IL2, IL2RA, TNF
42positive regulation of B cell proliferationGO:003089010.0IL2, IL4, TNFRSF4
43positive regulation of protein phosphorylationGO:00019349.9IFNG, IL2, IL4, TNF
44defense response to bacteriumGO:00427429.9IFNG, IL10, NOD2, TNF
45positive regulation of T cell proliferationGO:00421029.9IFNG, IL2, IL2RA, IL4
46apoptotic signaling pathwayGO:00971909.9FASLG, TNF, TNFRSF4
47positive regulation of activated T cell proliferationGO:00421049.8IL18, IL2, IL2RA, IL4
48positive regulation of tyrosine phosphorylation of STAT proteinGO:00425319.6IFNG, IL18, IL2, IL4
49cell-cell signalingGO:00072679.6FASLG, IL10, IL18, IL2
50inflammatory responseGO:00069549.4IL10, IL18, IL2RA, TNF, TNFRSF4

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1growth factor activityGO:00080839.4IL10, IL2, IL4
2cytokine activityGO:00051258.4FASLG, IFNG, IL10, IL18, IL2, IL4

Sources for Acute Graft Versus Host Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet